Enliven Therapeutics Stock
Enliven Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Richard A. Fair
- Employees
- 67
- Market cap
- $2.7 B
- IPO
- 12/03/2020
Enliven Therapeutics, Inc. is a biopharmaceutical company in the healthcare / biotechnology sector based in Boulder, Colorado. The company's research focuses on the clinical development of small molecule therapeutics for cancer treatment. Its portfolio includes the kinase inhibitor ELVN-001, which is currently being…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Enliven Therapeutics stock: price history
1D
-5.1%
1W
-8.9%
1M
-24.0%
6M
-22.4%
YTD
+142.3%
1Y
+71.6%
2Y
+32.7%
5Y
+154.9%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~0% stronger price swings than usual
Enliven Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Enliven Therapeutics is a biopharmaceutical company in the clinical development stage. The business model is based on the discovery and advancement of small-molecule therapeutics for the treatment of cancer diseases. The focus is on specific drug candidates such as kinase inhibitors for the treatment of chronic myeloid leukemia as well as indications with abnormal HER2 gene mutations. The current emphasis is on conducting Phase 1 clinical trials to validate the therapeutic approaches.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Enliven Therapeutics
Analyst assessment of Enliven Therapeutics
PRICE TARGET LOW
US$65.00
CONSENSUS
US$75.14
MEDIAN
US$78.00
PRICE TARGET HIGH
US$82.00
0
STRONG BUY
9
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 18/08/2026
Enliven Therapeutics stock metrics
P/E
-22.76
P/B
2.76
EV/EBITDA
-24.58
RETURN ON EQUITY
-3.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
63.8%
FLOAT SHARES
46,782,960
AVG. DAILY VOLUME (30D)
1,447,765
Insider transactions (SEC)
Garland J. Scott
Garland J. Scott
Collins Helen Louise
Collins Helen Louise
Hohl Benjamin
Attention
Price since yesterday: -5.1%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Enliven Therapeutics stock
What does Enliven Therapeutics do?
Enliven Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Richard A. Fair, the company employs around 67 people.
The IPO was on 12/03/2020; the stock trades on NASDAQ under the ticker ELVN.
What do analysts say about Enliven Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
The average price target is US$75.14, ranging from US$65.00 to US$82.00, with a median of US$78.00.
This is an external assessment, not a statement by Market Jury.
When does Enliven Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does Enliven Therapeutics pay a dividend?
No, Enliven Therapeutics currently does not pay a dividend.
Which stocks are comparable to Enliven Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Enliven Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Enliven Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.